Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Recruiting

Phase 1

Phase 2

Rintatolimod, Celecoxib, Interferon Alpha 2bRintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Sponsor:

Roswell Park Cancer Institute

Code:

NCT05756166

Conditions

Anatomic Stage IV Breast Cancer AJCC v8

Metastatic Triple-Negative Breast Carcinoma

Unresectable Triple-Negative Breast Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy

Biospecimen Collection

Celecoxib

Computed Tomography

Interferon Alpha-2

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Roswell Park Cancer Institute on 2025-03-25.